FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing study

The FDA on Friday revised the label for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys to add a boxed safety warning and restrict the therapy’s use to ambulatory patients, reflecting changes that the agency and ...